ICAM1 and plasma cell myeloma: Treatment with IMiDs decreases the expression of vascular-cell-adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), which play key roles in the adhesion of multiple myeloma to the bone marrow compartment [24].